Novonesis_Logo (1).png
The era of biosolutions. Outlook upgraded for 2024
June 17, 2024 13:09 ET | Novozymes A/S
Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to...
Novonesis_Logo (1).png
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
June 06, 2024 05:28 ET | Novozymes A/S
   June 6, 2024Company announcement No. 20  Incentive program for the Executive Leadership Team 2024-2026 In line with previous year, a new long-term incentive program (LTI) for the...
Novonesis_Logo (1).png
Trading by management and close relations of management
May 31, 2024 05:26 ET | Novozymes A/S
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Novonesis_Logo (1).png
Trading by management and close relations of management
May 29, 2024 10:59 ET | Novozymes A/S
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Novonesis_Logo
Trading by management and close relations of management
May 17, 2024 06:39 ET | Novozymes A/S
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Novonesis_Logo (1).png
Trading by management and close relations of management
May 08, 2024 09:21 ET | Novozymes A/S
Please read the full announcement in PDF Attachment 2024_16_Trading_By_Management ...
Novonesis_Logo (1).png
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration
May 03, 2024 01:57 ET | Novozymes A/S
For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA...
Novonesis_Logo (1).png
Trading statement Q1 2024
May 03, 2024 01:56 ET | Novozymes A/S
Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4%...
Novonesis_Logo (1).png
Resolutions from the annual shareholders’ meeting 2024
April 30, 2024 12:02 ET | Novozymes A/S
Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:•  Approval of the audited Annual Report for 2023•  Approval of distribution of profit with payment of an...
Novonesis_Logo (1).png
Invitation to the annual shareholders’ meeting
April 08, 2024 09:17 ET | Novozymes A/S
The annual shareholders’ meeting will be held on Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark. The distribution of profit will be addressed at the meeting and...